Barriers that Inhaled Particles Encounter.

Area of Science:

• Pharmaceutical Sciences
• Respiratory Medicine
• Biotechnology

Background:

• Inhalable drug carriers (nanoparticles, microparticles, liposomes, micelles) must achieve lung deposition and controlled drug release.
• The respiratory system presents significant physiological, mechanical, and chemical barriers to inhaled particles.
• These barriers impede deep lung deposition, reduce particle residence time, and diminish therapeutic efficacy.

Purpose of the Study:

• To elucidate the lung's defense mechanisms against inhaled particulate drug carriers.
• To inform the design of inhalable drug carriers for improved lung deposition and retention.
• To enhance the therapeutic outcomes of inhaled medications.

Main Methods:

• Review and synthesis of existing literature on lung physiology and particle-lung interactions.
• Analysis of mechanical barriers (e.g., mucociliary clearance).
• Evaluation of chemical and immunological barriers (e.g., mucus, alveolar macrophages).

Main Results:

• Inhaled particles face multiple defense lines including mucociliary clearance, mucus entrapment, and phagocytosis.
• Lung barriers significantly influence particle fate, residence time, and deposition patterns.
• Understanding these barriers is essential for engineering effective inhalable drug delivery systems.

Conclusions:

• Effective design of inhalable drug carriers necessitates a comprehensive understanding of lung defense mechanisms.
• Particle engineers must address mechanical, chemical, and immunological barriers to optimize drug delivery to the lungs.
• Knowledge of these barriers will lead to improved therapeutic efficacy of inhaled drugs.